-
EGFR 20ins mutant lung cancer, Amivantamab is better than the existing treatment!
Time of Update: 2022-04-27
Amivantamab compared with real-world therapies in patients with advanced non- small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
-
JEV (IF=26) Peking University Shen Lin/Zhang Xiaotian et al developed a new scoring system to predict and monitor the outcome of immunotherapy for gastric cancer
Time of Update: 2022-04-27
Overall, by proposing a protein-level plasma EV score that can effectively predict and monitor immunotherapy outcomes in GC, this research work facilitates clinical patient selection and decision-making and provides insights into immunotherapy-related microenvironmental changes and current ICIs.
-
Hypoalbuminemia, pleural effusion... MET-TKI adverse event management method, do you know?
Time of Update: 2022-04-27
*Only for medical professionals to read and reference, learn quickly! Targeted therapy plays an important role in the comprehensive treatment of non-small cell lung cancer (NSCLC) . In recent years,
-
Summary of studies on immunotherapy combined with platinum and etoposide regimens in the first-line treatment of extensive-stage small cell lung cancer ELCC 2022
Time of Update: 2022-04-27
Clinical and Molecular Characteristics of Long-Term Surviving Patients in the CASPIAN Study Background The Phase III study of the CASPIAN trial showed that first-line durvalumab combined with EP chemotherapy significantly improved OS compared with EP chemotherapy, with a median follow-up > 3 This benefit persisted after one year (HR 0.
-
Inventory of 120 clear carcinogens, these 20 most common in life!
Time of Update: 2022-04-27
Rubber manufacturing industry: In the production process, there are many chemical additives, and it is easy to come into contact with carcinogens such as aniline, which can induce bladder cancer, gastric cancer, lung cancer and leukemia .
-
The latest research progress of six rare targets in lung cancer, one article inventory
Time of Update: 2022-04-27
Research progress in the treatment of rare gene mutations in non-small cell lung cancer [J].
[5]Zhou Jie. Research progress of NTRK gene fusion and TRK inhibitor in non-small cell lung cancer[J].
-
Radioligand therapy opens up new horizons for mCRPC treatment Prof. Feng Wang comprehensively interprets 177Lu-PSMA-617 and 177Lu-PSMA-I&T therapy
Time of Update: 2022-04-27
Coincidentally, recently, the efficacy and safety results of 177Lu-PSMA-I&T for mCRPC in an Asian population led by Professor Wang Feng from Nanjing First Hospital were published in the internationally renowned journal frontiers in oncology .
-
Baseline SUVmax identifies early FL with high risk of recurrence
Time of Update: 2022-04-27
Based on this, some researchers have carried out related studies to determine the value of PET indicators at baseline in predicting the prognosis of FL patients, and to establish a link with the molecular markers of FL tumor cells and their immune cell infiltration .
-
Sitting for a long time increases the risk of death by 5 times!
Time of Update: 2022-04-27
Regarding the intensity and mode of exercise, the ACS Guidelines state that cancer patients should try to achieve the following exercise goals, provided that the doctor believes that physical activity is safe to perform [2]: 150-300 minutes of moderate-intensity exercise per week .
-
Muscle exercise + aerobic exercise reduces the risk of cancer death by 28%!
Time of Update: 2022-04-27
It was found that combining muscle-strengthening training with aerobic exercise reduced the overall risk of cancer death by 28% (RR=0.
Depression: Moderate-intensity aerobic training 3 times per week for at least 12 weeks, or combined aerobic and resistance training twice per week for 6 to 12 weeks, significantly reduced depression symptoms in cancer survivors during and after treatment .
-
Whole-course management of real-world EGFR-mutant lung adenocarcinoma targeting combined with anti-angiogenic therapy mode China Thoracic Oncology Conference
Time of Update: 2022-04-27
Unsure of the voting result: Lin Jie (Chief Physician of the Radiotherapy Department of the Second Affiliated Hospital of Kunming Medical University): Personally choose to change the third-generation EGFR-TKI immediately .
-
"The Lancet" sub-issue: Not better than chemotherapy, ADC drugs challenge malignant pleural mesothelioma and get negative results; T-DXd is planned to be included in breakthrough therapy in China!
Time of Update: 2022-04-27
Screenshot from journal website This randomized, open-label, phase II study at 76 hospitals in 14 countries enrolled adults (age ≥18 years) with unresectable locally advanced or metastatic malignant pleural mesothelioma, Eastern United States Patients with a Cooperative Oncology Group (ECOG) performance status score of 0-1 and who had disease progression after first-line platinum-based + pemetrexed chemotherapy (with or without bevacizumab) .
-
Kite's CAR-T therapy approved by FDA for second-line treatment of lymphoma
Time of Update: 2022-04-27
S. Food and Drug Administration announced that it has approved the expanded scope of the CD19-targeted CAR-T therapy Yescarta (axicabtagene ciloleucel) developed by Kite Pharma, a subsidiary of Gilead Sciences, for the second-line treatment of large B-cell lymphoma (LBCL).
-
Professor Lu Shun led the severtinib study on the international academic stage for the third time, bringing super long-term survival data
Time of Update: 2022-04-27
The Phase II clinical study of sevolitinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation, led by Professor Lu Shun of the Chest Hospital Affiliated to Shanghai Jiaotong University, was successfully selected for the 2022 ELCC oral report.
-
"The Lancet Respiratory Medicine": One Million Chinese People's Congress Survey!
Time of Update: 2022-04-27
Subgroup analysis suggested that the significant associations between one-time LDCT screening and reduction in lung cancer mortality/all-cause mortality in high-risk lung cancer groups were mainly found in males, 55-74 years old, and living in high-income areas such as Beijing, Zhejiang, and Jiangsu.
-
[Science Sub-Journal] Destroy the repair mechanism of cancer cells after treatment and eradicate residual cancer cells!
Time of Update: 2022-04-27
In their search for ways to prolong the survival benefits of targeted therapies, a team led by researchers at Duke Cancer Institute has identified a potential new strategy for disrupting the repair mechanisms that cancer cells use after treatment, blunting their regeneration ability .
-
Signet ring cell carcinoma again!
Time of Update: 2022-04-27
If early detection, early diagnosis, and early treatment can be achieved, gastric signet ring cell carcinoma is the same as other types of gastric cancer, and the prognosis is very good .
-
Lancet: K drug adjuvant treatment of high-risk stage II melanoma significantly improves RFS; domestic PD-1 refreshes chemoimmune combined with first-line treatment of advanced lung squamous cell carcinoma OS records tumor intelligence
Time of Update: 2022-04-27
Domestic PD-1 monoclonal antibody refreshes the record of immunotherapy combined with chemotherapy in the first-line treatment of advanced squamous cell carcinoma of the lung Second-line treatment of LBCL, CAR-T therapy approved in my country for clinical 01Lancet: Pembrolizumab adjuvant therapy for high-risk stage II melanoma significantly improves recurrence-free survival!
-
Beware of cancer risks behind artificial sugar substitutes!
Time of Update: 2022-04-27
Charlotte Debras, from the Research Laboratory for Nutritional Epidemiology (EREB), University Paris XIII, and her colleagues found that high intake of artificial sugar substitutes, especially aspartame, was significantly associated with a 22% higher risk of breast cancer , was significantly associated with a 15% increased risk of obesity-related cancers [1] .
-
Nimotuzumab made a major breakthrough in the treatment of pancreatic cancer, and the results of the phase 3 study were selected for the 2022 ASCO oral report
Time of Update: 2022-04-27
The registration clinical study (Notable study) of locally advanced or metastatic pancreatic cancer compared with gemcitabine in the treatment of K-Ras wild-type successfully met the pre-specified primary endpoint.
